间充质干细胞来源的外泌体在心肌梗死治疗中的研究进展  

Exosomes Derived from Mesenchymal Stem Cell in Treatment of Myocardial Infarction

作　　者：俞佳丽 景雨 张剑[1] 陈楚[1] 陆齐[1] 顾周山[1] 陈子微 周大胜 景宏美[1] 潘丽华[1] YU Jiali;JING Yu;ZHANG Jian;CHEN Chu;LU Qi;GU Zhoushan;CHEN Ziwei;ZHOU Dasheng;JING Hongmei;PAN Lihua(Department of Cardiology,Affiliated Hospital of Nantong University,Nantong 226001,Jiangsu,China;Medical College of Nantong University,Nantong 226001,Jiangsu,China)

机构地区：[1]南通大学附属医院心血管内科,江苏南通226001 [2]南通大学医学院,江苏南通226001

出　　处：《心血管病学进展》2022年第4期341-343,351,共4页Advances in Cardiovascular Diseases

基　　金：2020年南通市市级科技计划(指导性)项目(MSZ20082)。

摘　　要：心肌梗死的高发病率和高死亡率严重危害了人类健康。近年来,间充质干细胞被广泛用于心肌梗死和缺血性心力衰竭的治疗中。研究表明,间充质干细胞移植更多依赖旁分泌作用改善心脏功能,而外泌体被认为是重要的旁分泌介质。现综述近年来间充质干细胞来源的外泌体在心肌梗死治疗中相关作用机制的研究进展和应用前景。The high incidence and mortality of myocardial infarction seriously endanger human health.In recent years,mesenchymal stem cell have been widely used in the treatment of myocardial infarction and ischemic heart failure.Studies have shown that mesenchymal stem cell transplantation relies more on paracrine effects to improve heart function,and exosomes are considered to be important paracrine mediators.This article summarizes the recent research progress and application prospects of exosomes derived from mesenchymal stem cell in the treatment of myocardial infarction.

关 键 词：间充质干细胞 外泌体 心肌梗死 

分 类 号：R54[医药卫生—心血管疾病]